TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00513383

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Part A: Intravenously once a week for 7 weeks Part B (Induction Chemotherapy): Intravenously on Day 1 of a 21-day cycle for 3 cycles Part B (After Induction chemotherapy): Intravenously once a week for 7 weeks at the dosing level established during Part A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panitumumab
Description: Part A: Intravenously once a week for 7 weeks Part B (Induction Chemotherapy): Intravenously on Day 1 of a 21-day cycle for 3 cycles Part B (After Induction chemotherapy): Intravenously once a week for 7 weeks at the dosing level established during Part A

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Part A: Intravenously once weekly for 7 weeks Part B (Following induction therapy): Intravenously once a week for 7 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Part A: Intravenously once weekly for 7 weeks Part B (Following induction therapy): Intravenously once a week for 7 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Part A: Intravenously once weekly for 7 weeks Part B (Following induction therapy): Intravenously once a week for 7 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Part A: Intravenously once weekly for 7 weeks Part B (Following induction therapy): Intravenously once a week for 7 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Description: Part A: Daily five days a week for 7 weeks Part B (After Induction therapy): Daily five days a week for 7 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiation Therapy
Description: Part A: Daily five days a week for 7 weeks Part B (After Induction therapy): Daily five days a week for 7 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Intravenously at one of two dose levels on days 1-4 of a 21-day cycle for three cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Intravenously on day 1 of a 21-day cycle for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenously on day 1 of a 21-day cycle for 3 cycles
Study: NCT02992782

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: Home program of decongestive exercise and daily use of a compression sleeve

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and Compression Garment
Description: Decongestive progressive resistance exercise using flat-knit garment and daily use of a compression sleeve

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and Adjustable Compression Wrap
Description: Decongestive progressive resistance exercise using adjustable compression wrap and daily use of a compression sleeve
Study: NCT02916810

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active rTMS stimulation
Description: Participants will receive two rTMS sessions in each treatment visit for up to 22 visits within about 6 weeks. There is a 30-minute rest between the two rTMS sessions.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS stimulation
Description: Participants will receive two sham rTMS sessions in each treatment visit for up to 22 visits within about 6 weeks. There is a 30-minute rest between the two sham rTMS sessions.
Study: NCT01737346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lomustine and procarbazine
Description: 1 cycle (4 weeks) includes CCNU 75mg/m2 (D1) and procarbazine 60mg/m2 (D11-D24)by mouth for up to 6 cycles
Study: NCT05756231

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SIHT-16
Description: a pencil-paper assessment tool.
Study: NCT03514069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib
Description: Starting dose ruxolitinib 10 mg twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ruxolitinib
Description: Starting dose ruxolitinib 10 mg twice daily

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: 60gy for 6 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: 60gy for 6 weeks
Study: NCT01951534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Breast Reconstruction Decisional Aid (BRDA)

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Study: NCT03514069

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: temozolomide
Description: 75mg/m2
Study: NCT02114229

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Description: The guidelines for this protocol were developed to maximize the curative potential of radiation therapy and minimize the risk of treatment complications for children with newly diagnosed CNS AT/RT. Focal irradiation is indicated for children \< 36 months with no evidence of metastatic disease. Craniospinal irradiation is indicated for children age \> 36 months.
Study: NCT02059499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imiquimod
Description: Given intra-anally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given intra-anally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04671771

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InnAVasc Arteriovenous Graft (IG) surgical implant
Description: The InnAVasc Arteriovenous Graft (IG) is a hemodialysis vascular access graft, intended for implantation in the lower or upper arm using standard vascular techniques, in patients requiring hemodialysis
Study: NCT02102620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra-articular injection with corticosteroid
Description: After rigorous antisepsis with alcoholic 0.5% chlorhexidine. Sterile insulin syringe BD ™ Ultra Fine needles 8 mm x 0.3 mm 30 G) was used in all patients. The anatomical place used for needle entry was located in the dorsal - lateral joint aspect. After the procedure, the injected joint was immobilized for 48 hours.
Study: NCT05840848

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Control beta-carotene supplement plus Placebo
Description: 15 mg beta-carotene supplement from BIOVEA consumed before breakfast together with an empty capsule.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control beta-carotene supplement plus iron Supplement
Description: 15 mg Beta-carotene supplement from BIOVEA consumed before breakfast together with 25 mg iron (FeSO4; Woerwag Pharma GmbH \& Co. KG, Boeblingen, Germany)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control beta-carotene supplement plus zinc Supplement
Description: 15 mg Beta-carotene supplement from BIOVEA consumed before breakfast together with 30 mg zinc (ZnSO4; Woerwag Pharma GmbH \& Co. KG, Boeblingen, Germany)
Study: NCT04044222

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifosfamide
Description: IV
Study: NCT00394355

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate dry powder inhaler
Description: 400 mcg MF DPI via a breath-actuated, dry-powder inhaler and a placebo tablet given by mouth once daily in the evening for 1 year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mometasone furoate dry powder inhaler
Description: 200 mcg MF DPI via a breath-actuated, dry-powder inhaler and a placebo tablet given by mouth once daily in the evening for 1 year.
Study: NCT02102620

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intra-articular injection with lidocaine
Description: After rigorous antisepsis with alcoholic 0.5% chlorhexidine. Sterile insulin syringe BD ™ Ultra Fine needles 8 mm x 0.3 mm 30 G) was used in all patients. The anatomical place used for needle entry was located in the dorsal - lateral joint aspect. After the procedure, the injected joint was immobilized for 48 hours.
Study: NCT03014895

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion
Study: NCT00990821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg MK-0517 (non-PS80)
Description: MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
Study: NCT00394355

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate hydrofluoroalkane (HFA)
Description: 250 mcg FP HFA given twice a day via a metered-dose inhaler and a placebo tablet given once daily in the evening for 1 year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast
Description: 10 mg given once daily in the evening by mouth for 1 year.
Study: NCT03094312

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dynamic Spectral Imaging (ISD)
Description: cerebral stimulation: dynamic spectral imaging (ISD)
Study: NCT00424125

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Pharmacy Care
Description: Participants randomized to Enhanced Pharmacy Care will have their prescriptions electronically transmitted or faxed to one of the five participating pharmacies.~Pharmacists will then provide real-time, targeted education around the purpose and use of the new and refilled ICS medications to study participants and their families at each point of contact, including rationale for their use, device teaching, dosage review, and importance of compliance. Families randomized to enhanced care will also be contacted monthly by phone and mail with reminders to fill their controller medications prescriptions and to seek ongoing longitudinal asthma care with their primary care providers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Usual care.
Study: NCT02612064

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stannous Fluoride dentifice
Description: Experimental dentifrice containing 0.454% w/w stannous fluoride (1100ppm)
Study: NCT02612064

Intervention type: OTHER
Group type: OTHER
Intervention: Sodium Monofluorophosphate dentifrice
Description: Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)
Study: NCT03852043

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-intensity interval training
Description: The intervals of high intensity are conducted between 90 and 95 % of heart rate maximum (HRmax) and resting between 50 and 60 % of the HRmax 15 loads of 30 seconds at high intensity, with 60 seconds of recovery at loads of moderate intensity.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate-intensity continuous training
Description: The continuous training will be carried out at an intensity between 65 and 75% of the HRmax.
Study: NCT02249455

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acapella
Description: Treatment time for 20 min twice daily

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ELTGOL
Description: ELTGOL technique 20 min twice daily

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional physiotherapy
Description: Conventional physiotherapy was given twice daily for 20 min
Study: NCT01188109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Standard of care chemotherapy and dosage~Dose - 1000 mg/m²~Schedule - Days 1 and 15; Q 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Dose - 50 mg/m²~Schedule - Days 1 and 15; Q 28 days
Study: NCT03367039

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ProDisc-C vivo
Description: Total Disc Replacement using ProDisc-C vivo.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Anterior cervical discectomy fusion
Description: Anterior Cervical Discectomy and Fusion
Study: NCT04065503

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Probiotic Strains
Description: A commercial product containing L. helveticus R0052, L. casei HA-108, B. breve HA-129, and B. longum R0175 and S. thermophilus HA-110 be given to healthy adults across a 10-week open label pilot study.
Study: NCT02930473

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NIC Psychotherapeutic Intervention(s) for Anxiety
Description: Patients will be treated by NIC psychotherapeutic intervention(s) for anxiety (e.g. anxiety reduction) plus psychopharmaceuticals prescribed by their psychiatrist.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psychopharmaceuticals (any drugs prescribed by the psychiatrist)
Description: Patients will be treated only by psychopharmaceuticals prescribed by their psychiatrist.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Psychopharmaceuticals (any drugs prescribed by the psychiatrist)
Description: Patients will be treated only by psychopharmaceuticals prescribed by their psychiatrist.
Study: NCT00990821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg MK-0517 (non-PS80)
Description: MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg MK-0517 (non-PS80)
Description: MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100 mg MK-0517 (non-PS80)
Description: MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 150 mg MK-0517 (Non-PS80)
Description: MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching MK-0517
Study: NCT03014895

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E3112
Description: Intravenous infusion
Study: NCT00990821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching MK-0517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo matching MK-0517

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 40 mg Aprepitant
Description: Aprepitant, oral, tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 125 mg Aprepitant
Description: Aprepitant oral tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 125 mg Aprepitant
Description: Aprepitant oral tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 125 mg Aprepitant
Description: Aprepitant oral tablet, single dose
Study: NCT03778034

Intervention type: OTHER
Intervention: female with Forward head posture
Description: measuring tmj proprioception with open eyes and closed eyes for mouth opening,right deviation,left deviation and protrusion,cranio vertebral angle and shoulder angle

Intervention type: OTHER
Intervention: healthy female without (FHP)
Description: measuring tmj proprioception with open eyes and closed eyes for mouth opening,right deviation,left deviation and protrusion,cranio vertebral angle and shoulder angle
Study: NCT01120249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: everolimus
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT01743950

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 10mg/kg every 2weeks.
Study: NCT03014895

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E3112
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E3112
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E3112
Description: Intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E3112
Description: Intravenous infusion
Study: NCT02792894

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family networks program
Description: Intervention, Family networks Program (FaNs), is administered once weekly over 9-10 weeks in a group format over 3 hours per sessions. Family networks Program (FaNs) is based on WHO mhGAP module for developmental disorders and incorporates WHO parent skills training program for children with developmental disorders and delays. Parents Skills Training Program includes modules on communication, play, daily living skills, managing challenging behavior, coping with stress. Intervention is provided by the family volunteers (members of community, mostly women, who have a child affected in their families).
Study: NCT02960035

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50mg etanercept
Description: Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 50mg per week
Study: NCT00990821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 125 mg Aprepitant
Description: Aprepitant oral tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 125 mg Aprepitant
Description: Aprepitant oral tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 125 mg Aprepitant
Description: Aprepitant oral tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 125 mg Aprepitant
Description: Aprepitant oral tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 125 mg Aprepitant
Description: Aprepitant oral tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 125 mg Aprepitant
Description: Aprepitant oral tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 125 mg Aprepitant
Description: Aprepitant oral tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 mg Midazolam
Description: Midazolam oral tablet, single dose
Study: NCT01095809

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: 2.5mg at baseline, week 4 and 8. Beyond this initial period if needed reinjection criteria are described in protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triamcinolone acetonide
Description: 2 mg at baseline; frequency every three months if needed. reinjection criteria are described in protocol
Study: NCT01702155

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFP-10917
Study: NCT01801813

Intervention type: OTHER
Intervention: Collecting pre-operative, per-operative data, neuro-radiological data and post-operative neuro-surgery complications
Study: NCT01568112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00012 (dimethyl fumarate)
Description: Each capsule contains 120 mg dimethyl fumarate (DMF). Fast titration involves taking one 120 mg capsule in the morning and one in the evening (240 mg daily) for one week, and then escalating to a dose of 480 mg daily (two capsules morning and evening) for the remainder of the study.Slow titration expands the dose escalation time to 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00012 (dimethyl fumarate)
Description: Each capsule contains 120 mg dimethyl fumarate (DMF). Fast titration involves taking one 120 mg capsule in the morning and one in the evening (240 mg daily) for one week, and then escalating to a dose of 480 mg daily (two capsules morning and evening) for the remainder of the study.Slow titration expands the dose escalation time to 4 weeks.
Study: NCT01743950

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 10mg/kg every 2weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 10mg/kg every 2weeks.
Study: NCT01568112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00012 (dimethyl fumarate)
Description: Each capsule contains 120 mg dimethyl fumarate (DMF). Fast titration involves taking one 120 mg capsule in the morning and one in the evening (240 mg daily) for one week, and then escalating to a dose of 480 mg daily (two capsules morning and evening) for the remainder of the study.Slow titration expands the dose escalation time to 4 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00012 placebo
Description: Placebo matching BG00012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00012 placebo
Description: Placebo matching BG00012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BG00012 placebo
Description: Placebo matching BG00012

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BG00012 placebo
Description: Placebo matching BG00012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA
Description: 325 mg microcoated aspirin (ASA)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA placebo
Description: Placebo matching aspirin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASA placebo
Description: Placebo matching aspirin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ASA placebo
Description: Placebo matching aspirin
Study: NCT02756299

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Support
Description: General information about OSA and PAP treatment at baseline and additional polysomnography chart viewing from both diagnostic and titration nights

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Support
Description: General information about OSA and PAP treatment at baseline
Study: NCT04063878

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conometric Abutment and Conometric Final Cap
Description: Conometric concept developed by Dentsply Sirona Implants for implant systems Ankylos, Astra Tech Implant System and Xive.
Study: NCT01601639

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic Band Ligation
Description: Endoscopic band ligation device: 6 Shooter Saeed Multi-Band Ligator (Cook Medical/Endoscopy)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Argon plasma Coagulation (APC) for GAVE
Description: APC treatment for gastric antral vascular ectasia (GAVE) Argon plasma coagulation device: ERBE VIO 300D (Elektromedizin GmBH)